Author:
Chen Dan-qi,Wang Xin,Chen Lin,He Jin-xue,Miao Ze-hong,Shen Jing-kang
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine
Reference22 articles.
1. Pallavicini MG . Cytosine arabinoside: Molecular, pharmacokinetic and cytokinetic considerations. Pharmacol Ther 1984; 25: 20738.
2. Rustum M, Raymakers RA . 1-β-Arabinofuranosylcytosine in therapy of leukemia: Preclinical and clinical overview. Pharmacol Ther 1993; 56: 307–21.
3. Beumer JH, Eiseman JL, Parise RA, Florian Jr JA, Joseph E, D'Argenio DZ, et al. Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor in mice. Cancer Chemother Pharmacol 2008; 62: 457–64.
4. Hsi D, Ho W . Distribution of kinase and deaminase of 1-β-D-Arabinofuranosylcytosine in tissue of man and mouse. Cancer Res 1973; 33: 2816–20.
5. Hamada A, Kawaguchi T, Nakano M . Clinical pharmacokinetics of cytarabine formulations. Clin Pharmacokinet 2002; 41: 705–18.
Cited by
30 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献